10-K: GRAIL 2025 Annual Report: Galleri Sales Up, Losses Narrow Amid Mixed Trial Results

GRAIL reports increased Galleri sales and reduced net losses in 2025, but faces challenges with a missed primary endpoint in the NHS-Galleri Trial and ongoing regulatory hurdles for broad reimbursement.

Summary

• Net loss for 2025 was $408.4 million, a significant reduction from $2.0 billion in 2024 and $1.5 billion in 2023.
• Adjusted EBITDA was $(320.6) million in 2025, compared to $(483.5) million in 2024 and $(523.9) million in 2023.
• Total revenue increased by 17% to $147.2 million in 2025 from $125.6 million in 2024.
• Screening revenue grew 28% to $138.6 million in 2025, driven by a 36% increase in Galleri sales volume, partially offset by a 6% decrease in Average Selling Price (ASP).
• Development services revenue decreased by 49% to $8.6 million in 2025, primarily due to a $7.0 million decrease from biopharmaceutical pilots and a $1.4 million decrease from research services.
• Research and development expenses decreased by 39% to $195.8 million in 2025, largely due to workforce reductions from the 2024 Restructuring Plan and substantial completion of automated platform development and PATHFINDER 2 enrollment.
• Goodwill and intangible assets impairment decreased by 98% to $28.0 million in 2025, compared to $1.4 billion in 2024, with the IPR&D asset fully impaired in 2025.
• The NHS-Galleri Trial did not meet its primary endpoint of statistically significant combined Stage 3 and 4 cancer reduction, but demonstrated a substantial reduction in Stage 4 cancer diagnoses and increased Stage 1 and 2 detection of deadly cancers.
• A Pre-Market Approval (PMA) application for Galleri was submitted to the FDA in January 2026, including PATHFINDER 2 Initial Results and NHS-Galleri Prevalent Screening Round Results.
• Completed a $325 million Private Investment in Public Equity (PIPE) transaction in October 2025, generating $311.3 million in net proceeds.
• Launched an At-the-Market (ATM) program in November 2025, raising $107.5 million in net proceeds in 2025.
• Announced a strategic collaboration with Samsung C&T and Samsung Electronics in October 2025, including a $110.0 million equity investment from Samsung Investors, subject to closing conditions.
• Robert Ragusa will retire as Chief Executive Officer on June 1, 2026, and Joshua Ofman, M.D., MSHS, has been appointed as his successor.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative report. While revenue growth and reduced net losses are positive, the failure of the NHS-Galleri trial to meet its primary endpoint and the full impairment of IPR&D assets are significant setbacks that introduce considerable uncertainty regarding future regulatory approvals, reimbursement, and market adoption, impacting long-term growth prospects despite recent capital raises.

Positives

• Net loss significantly reduced to $408.4 million in 2025 from $2.0 billion in 2024, indicating improved financial efficiency.
• Total revenue increased by 17% to $147.2 million in 2025, demonstrating commercial growth.
• Screening revenue grew 28% to $138.6 million, driven by a 36% increase in Galleri sales volume.
• PATHFINDER 2 Initial Results showed adding Galleri to recommended screenings led to a more than seven-fold increase in cancers found within a year, and approximately three-fold with prostate screening.
• NHS-Galleri Trial demonstrated a substantial reduction in Stage 4 cancer diagnoses (greater than 20% reduction in second and third screening rounds) and increased Stage 1 and 2 detection of deadly cancers.
• The NHS-Galleri Trial showed a four-fold higher cancer detection rate when compared to recommended screenings alone.
• Galleri's Positive Predictive Value (PPV) in PATHFINDER 2 Initial Results was 61.6%, substantially higher than the foundational CCGA study.
• Galleri's Cancer Signal of Origin (CSO) accuracy was 92% and false positive rate was 0.4% in PATHFINDER 2 Initial Results, consistent with CCGA.
• The SYMPLIFY study showed an updated PPV of 84.2% with extended follow-up in symptomatic patients, with 57.1% of later-diagnosed cancers correctly predicted by CSO.
• Successful capital raises: $311.3 million net from PIPE and $107.5 million net from ATM program in 2025, strengthening liquidity.
• Strategic collaboration with Samsung for commercialization in South Korea and other Asian markets, including a $110.0 million equity investment, expands international reach.
• The Nancy Gardner Sewell Medicare MCED Coverage Act became law in February 2026, creating a Medicare coverage benefit category for multi-cancer early detection tests.
• Maintains a strong intellectual property portfolio with approximately 408 licensed and 221 owned/co-owned issued patents globally.
• Operates a high-capacity, CAP-accredited and CLIA-certified laboratory in Durham, NC, capable of processing up to one million tests per year with significant automation.

Negatives

• The NHS-Galleri Trial did not meet its primary endpoint of statistically significant combined Stage 3 and 4 cancer reduction, which may negatively impact perceptions of clinical utility.
• Development services revenue decreased by 49% in 2025, indicating a slowdown in this segment.
• Continues to incur significant net losses since inception, with an accumulated deficit of $10.2 billion as of December 31, 2025.
• The IPR&D assets were fully impaired in 2025, resulting in no remaining carrying value, reflecting a re-evaluation of certain development programs.
• The perpetual royalty payment obligation to Illumina (7-9% of net sales in oncology) will resume on December 24, 2026, or earlier upon change of control, which will impact future gross margins.
• Experienced and may continue to experience increased turnaround times, re-processing costs, and sample failures with the updated commercial version of Galleri launched in late 2024.
• Dependence on sole suppliers (Illumina for sequencers/reagents, Madison for blood tubes, Twist for DNA panels) creates supply chain vulnerabilities.
• The Samsung Investment closing is subject to regulatory approvals (e.g., CFIUS) and may be delayed or not close at all.
• The perceived value of employee equity awards (RSUs) was substantially lower after the Spin-Off conversion, potentially impacting employee retention.
• A potential interim impairment test of long-lived intangible assets is expected in Q1 2026 due to a material decrease in market capitalization following the NHS-Galleri trial results.

Risks

• Operating in a rapidly evolving field with a limited operating history makes it difficult to evaluate the current business and predict future performance.
• Anticipate continued significant net losses for the coming years.
• Products or future products may not perform as expected, and clinical study results may not be replicated in post-market or real-world settings.
• The clinical study process is lengthy and expensive with uncertain outcomes, and future delays or negative data may occur.
• A substantial majority of revenue is generated from sales of Galleri, making the company highly dependent on its success.
• Inadequate coverage and reimbursement from third-party payors would limit the ability to expand access to products and overall commercial success.
• Commercial products may fail to achieve the degree of market acceptance necessary for commercial success.
• Regulatory uncertainty regarding Laboratory Developed Tests (LDTs) following the vacating of the FDA's LDT Final Rule.
• The regulatory clearance, approval, or certification processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable.
• Multi-cancer detection tests are a new approach to cancer screening, presenting novel and complex issues for FDA review, with no assurance of timely approval or specific intended use.
• Inability to generate sufficient revenue to offset ongoing operating expenses and achieve and maintain profitability, especially with perpetual royalties to Illumina and the Chinese University of Hong Kong.
• Inability to develop and commercialize new products, including enhanced versions of current products.
• The market for products could be impaired if similar third-party products are developed and do not perform as intended or cause harm.
• Failure to obtain additional financing may prevent expansion of commercialization efforts or development of additional products.
• Products resulting in direct or indirect participant or patient harm or injury could lead to significant reputational and liability risks.
• Reliance on Illumina as a sole supplier for next-generation sequencers and associated reagents, Madison Industries for blood collection tubes, and Twist Bioscience Corporation for DNA panels, and a limited number of other suppliers.
• If facilities become inoperable, the ability to provide products will be significantly impaired.
• Operations and business are materially dependent on various third parties, including information technology, sample collection, processing, and patient-facing service providers, any of which could experience disruption.
• Inability to scale operations successfully to support demand for products.
• Failure to attract, motivate, and retain highly qualified personnel.
• Information technology systems, or those used by third-party collaborators, may fail or suffer cybersecurity incidents or cyberattacks.
• Quarterly results of operations may fluctuate significantly or fall below expectations, causing stock price volatility.
• Inability to obtain and maintain intellectual property protection, or if the scope is not sufficiently broad, third parties could commercialize similar technologies.
• Failure to comply with obligations in intellectual property license agreements could lead to loss of license rights.
• Potential indemnification obligation to Illumina if the Spin-Off's non-recognition treatment for U.S. federal tax purposes is challenged.
• Numerous restrictions agreed to in the Tax Matters Agreement to preserve the non-recognition treatment of the Spin-Off may reduce strategic and operating flexibility.
• Historical financial data is not necessarily representative of results as a separate, publicly traded company.
• No market for common stock existed prior to June 24, 2024, and an active trading market may not be sustained, leading to stock price fluctuations.
• Negative evaluations of stock by securities analysts could cause the stock price to decline.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies.
• Operating as an emerging growth company (EGC) may result in a less active trading market and higher stock price volatility.
• Substantial sales of common stock by Illumina or other significant shareholders could cause the stock price to decline.
• Misleading, untruthful, or unsubstantiated labeling, advertising, marketing, or promotional practices could cause significant harm.
• The evolving regulatory framework for AI Technologies may limit the ability to use such technologies or increase compliance costs.
• Changes in funding, leadership, resources, or prioritization in U.S. or international governments (e.g., FDA) could hinder development, approval, or reimbursement.
• Misuse or off-label use of products may harm reputation, result in injuries leading to product liability suits, or costly investigations/sanctions.
• Failure to comply with federal, state, and foreign laboratory and other applicable licensing and registration requirements could prevent performing tests or disrupt business.
• Data from clinical trials announced or published before completion may change as more patient data become available and are subject to audit and verification procedures.
• Any product for which regulatory authorization is obtained will be subject to extensive ongoing regulatory requirements, with penalties for non-compliance.
• Obtaining regulatory authorization in one jurisdiction does not guarantee success in others.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• ESG, DEI, anti-ESG, and anti-DEI sentiment could impact reputation and business.

Future Outlook

GRAIL expects to continue incurring operating losses for at least the next several years but believes existing cash and marketable securities will fund operations into 2030, with additional financing likely required thereafter. Research and development expenses are projected to decrease over the next three years due to reduced investment in non-Galleri programs and completion of key milestones. Sales and marketing, and general and administrative expenses are expected to increase in absolute terms but decrease as a percentage of revenue over time. The perpetual royalty payment obligation to Illumina (7-9% of net sales) will resume on December 24, 2026. The company plans to share final results from the full three-year NHS-Galleri trial in mid-2026 and expects interim results from the SUMMIT study in 2026 or 2027. FDA approval for Galleri is sought to unlock broad commercial payor coverage, with potential Medicare coverage for FDA-approved MCED tests as early as January 1, 2029, for specific age groups. GRAIL also intends to pursue inclusion in USPSTF guideline recommendations. The company plans to relocate its headquarters to Sunnyvale, California, with a lease commencing around October 1, 2026. An interim impairment test for long-lived intangible assets is anticipated in Q1 2026 due to recent market capitalization decrease.

Management Comments

• We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer.
• We have conducted what we believe is the largest clinical program in genomic medicine to date with data from over 385,000 participants that we believe demonstrate the clinical validation and clinical utility of Galleri in its intended use population.
• We believe that FDA approval could unlock broad coverage by large commercial payors in the United States.
• We believe the evidence of clinical utility from the trial, particularly the stage 4 reduction, increased stage 1 and 2 detection and a favorable trend over time in each screening round on combined stage 3 and 4 reduction, could be compelling to these systems even though the primary endpoint was not met.
• We believe the evidence package is even stronger when taken together with the positive results from our PATHFINDER 2 study.
• We believe our continued growth will be driven by... Our clinically-validated, commercially available, MCED screening test, Galleri.
• We believe our current facilities are sufficient to meet our current and anticipated near-term needs.
• We believe that our existing cash and cash equivalents, and short-term marketable securities will be sufficient to fund our projected operations for at least the next 12 months.
• We believe that the items subject to these further adjustments are not indicative of our ongoing operations due to their nature, especially considering the impact of certain items as a result of the Acquisition.
• We believe that the addition of new market entrants will help develop the market for MCED testing.
• We believe we are differentiated by our extensive and robust datasets generated from our clinical studies, our rigorous and objective approach to test development and research, our multidisciplinary capabilities leveraging the power of next-generation sequencing and advanced and trained machine learning algorithms and data science, our robust intellectual property portfolio, and our investment in our facilities and operational workflows.

Industry Context

StockSavvy.ai notes that the multi-cancer early detection (MCED) market is rapidly evolving with new entrants like Exact Sciences and Guardant Health introducing products in 2025. GRAIL's extensive clinical program and targeted methylation platform differentiate it, but increased competition and varying regulatory standards globally pose challenges. The creation of a Medicare coverage benefit category for MCED tests signals growing recognition and potential for market expansion, though the path to broad reimbursement remains complex and lengthy. The evolving regulatory landscape for AI technologies also presents a new layer of compliance and operational considerations for companies leveraging advanced algorithms in diagnostics.

Comparison to Industry Standards

• Galleri's PPV of 61.6% in PATHFINDER 2 is substantially higher than the company's foundational CCGA study and significantly higher than the PPV of all standard of care single-cancer screening tests.
• Galleri's false positive rate of 0.4% in PATHFINDER 2 is significantly lower than the false positive rate of all standard of care single-cancer screening tests.
• The NHS-Galleri Trial's four-fold higher cancer detection rate when compared to recommended screenings alone adds proof to a similar seven-fold increase shown in PATHFINDER 2, demonstrating superior detection yield compared to traditional methods.
• The SYMPLIFY study's updated PPV of 84.2% in symptomatic patients demonstrates strong performance in a distinct population, suggesting versatility beyond asymptomatic screening.
• GRAIL's targeted methylation approach showed superior performance and lower costs compared to whole-genome methylation and other genomic features (mutations, chromosomal alterations, fragment lengths) in head-to-head analyses, indicating a technological advantage.
• The company believes its extensive clinical program, with over 385,000 participants, is the largest in genomic medicine to date, differentiating it from competitors like Exact Sciences and Guardant Health who have launched MCED tests based only on case-controlled data, not interventional trials in intended use populations.

Management Changes

Corporate Governance

Legal Proceedings

• Three securities class action lawsuits (Kangas v. Illumina, Inc. et al., Roy v. Illumina, Inc. et al., and Louisiana Sheriffs Pension & Relief Fund v. Illumina, Inc. et al.) were consolidated into In re Illumina, Inc. Securities Litigation No. 23-cv-2082-LL-MMP.
• The consolidated complaints allege materially false and misleading statements and omitted material facts relating to Illumina's acquisition of GRAIL, violating sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.
• The court granted a motion to dismiss the second amended complaint with leave to amend on September 26, 2025, and a third amended complaint was filed on October 27, 2025, which the company moved to dismiss on December 12, 2025.
• The company denies the allegations and intends to vigorously defend the litigation.
• The SEC closed its investigation into Illumina and GRAIL regarding the acquisition and related disclosures on May 9, 2025.
• One in-licensed European patent (not related to Galleri or precision oncology) was maintained in amended form after an opposition, with an appeal pending. Two additional oppositions have been recently filed against other in-licensed European patents relating to Galleri, and these oppositions are currently pending.

Related Party Transactions

• Illumina, Inc. was a 14.5% shareholder after the Spin-Off on June 24, 2024, but sold 2,000,000 shares in Q4 2025, reducing its ownership to approximately 6.0% as of December 31, 2025. Illumina no longer meets the definition of a related party after November 17, 2025.
• A Supply and Commercialization Agreement with Illumina obligates a 7-9% perpetual royalty on net sales in oncology, suspended until December 24, 2026, or an earlier change of control.
• License agreements with the Chinese University of Hong Kong require low single-digit percentage royalties on net sales of products using licensed technology, subject to minimum annual guarantees.
• A Stock Purchase Agreement with Samsung C&T Corporation and Samsung Electronics Singapore Pte. Ltd. (Samsung Investors) involves the issuance and sale of 1,570,308 shares of common stock for approximately $110.0 million, subject to closing conditions including CFIUS approval.
• Entered into a Business Collaboration Agreement with Samsung C&T and a Strategic Opportunities Collaboration Agreement with Samsung Electronics.

Stakeholder Impact

• Shareholders face potential dilution from recent and future equity offerings, stock price volatility due to clinical trial results and regulatory uncertainties, and potential adverse impacts from ongoing legal proceedings.
• Employees experienced workforce reductions (approximately 25% of the workforce) as part of the 2024 Restructuring Plan, and there are concerns regarding retention due to the perceived lower value of RSU awards post-Spin-Off conversion. A leadership transition is underway with a new CEO.
• Customers (healthcare systems, employers, patients) may see continued availability of Galleri, with potential for broader access and reimbursement if FDA approval and USPSTF recommendations are achieved, but face uncertainty due to the NHS-Galleri trial's primary endpoint miss and the evolving LDT regulatory environment.
• Suppliers, particularly sole suppliers like Illumina, Madison, and Twist, are critical to operations, and any disruptions could impact the company's ability to provide products.
• Regulatory bodies, including the FDA, CMS, and NHS England, are actively engaged in the approval, coverage, and implementation processes for Galleri, and compliance with evolving data privacy and AI regulations is ongoing.

Next Steps

• Undertake additional analyses and extend the NHS-Galleri Trial follow-up period by 6-12 months.
• Submit detailed NHS-Galleri Trial results for presentation at the ASCO 2026 Annual Meeting.
• Pursue FDA approval for Galleri, with PMA submitted in January 2026.
• Pursue inclusion of Galleri in USPSTF guideline recommendations if FDA approval is obtained.
• NHS England will evaluate final NHS-Galleri Trial results (mid-2026) to determine implementation.
• Convene joint steering committee meetings with NHS England to discuss deployment approaches and target population groups.
• Explore potential additional strategic and operational collaborations with Samsung Electronics.
• Explore the launch of Galleri in select other international geographies, including through distributors.
• Perform an interim impairment test for long-lived intangible assets in Q1 2026.
• Joshua Ofman to assume Chief Executive Officer role on June 1, 2026.
• Robert Ragusa to serve as Senior Executive Advisor until March 12, 2027.
• Relocate headquarters to Sunnyvale, California, with lease commencement around October 1, 2026.

Key Dates

Recommendation

GRAIL's 2025 financial performance shows positive trends in revenue growth and reduced net losses, supported by successful capital raises. However, the missed primary endpoint in the NHS-Galleri Trial introduces significant uncertainty regarding broad market adoption, regulatory approvals, and reimbursement, which are critical for long-term profitability. While the company has a strong IP portfolio and a scalable platform, the reliance on sole suppliers and ongoing legal proceedings add to the risk profile. The stock price has already reacted negatively to the NHS-Galleri results, suggesting that much of the immediate downside may be priced in. Investors should hold to monitor the outcomes of the extended NHS-Galleri follow-up, FDA approval process, and progress on reimbursement, as these will be key determinants of future value.

Keywords

Multi-cancer early detection, Galleri, Liquid biopsy, Genomic medicine, Cancer screening, FDA approval, PMA, NHS-Galleri Trial, PATHFINDER 2, cfDNA, Methylation, Precision oncology, LDT, Reimbursement, Illumina, Samsung, Diagnostics, Biotechnology, Healthcare technology